Plain-English translation of NCT05807932 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether —a medication that works against certain blood cancer cells—can be safely added to the standard preparation drugs given before a stem cell transplant. Researchers want to find the right dose of and understand whether adding it helps people with high-risk blood cancers have better outcomes after transplant. This is an early-stage trial, so doctors are carefully watching for safety while also measuring how well the treatment works.
People with high-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and secondary acute myeloid leukemia have limited treatment options and often face poor outcomes. Researchers believe that adding this medication to the standard transplant preparation might help reduce the chance of cancer returning and improve survival, but first they need to confirm it is safe to use in this way.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will take the new medication by mouth once daily for about 6–8 days before receiving your stem cell transplant (the exact timeline depends on whether your cancer is active). You will also receive the standard preparation chemotherapy drugs during this same period. The trial involves regular visits to the hospital or clinic so doctors can monitor your blood counts, organ function, and side effects carefully. You will be followed closely throughout the transplant process and afterward to see how well the treatment works and to catch any side effects early.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Germany